Insider Buying: The Abeona Therapeutics Inc. (NASDAQ:ABEO) Just Bought US$500k Worth Of SharesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Insider Buying: The Abeona Therapeutics Inc. (NASDAQ:ABEO) Just Bought US$500k Worth Of SharesSimply Wall StSimply Wall St.January 2, 2020ReblogShareTweetShareView photosInvestors who take an interest in Abeona Therapeutics Inc. (NASDAQ:ABEO) should definitely note that insider Stefano Buono recently paid US$2.50 per share to buy US$500k worth of the stock. That certainly has us anticipating the best, especially since they thusly increased their own holding by 286%, potentially signalling some real optimism. See our latest analysis for Abeona Therapeutics Abeona Therapeutics Insider Transactions Over The Last YearNotably, that recent purchase by insider Stefano Buono was not the only time they bought Abeona Therapeutics shares this year. Earlier in the year, they paid US$7.91 per share in a US$546k purchase. That means that an insider was happy to buy shares at above the current price of US$3.27. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.While Abeona Therapeutics insiders bought shares last year, they didn't sell. Their average price was about US$4.01. This is nice to see since it implies that insiders might see value around current prices. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!NasdaqCM:ABEO Recent Insider Trading, January 2nd 2020MoreAbeona Therapeutics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.Insider OwnershipAnother way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$3.8m worth of Abeona Therapeutics stock, about 1.4% of the company. We consider this fairly low insider ownership.So What Do The Abeona Therapeutics Insider Transactions Indicate?It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Abeona Therapeutics insiders are expecting a bright future. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.But note: Abeona Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHow Does China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512) Stand Up To These Simple Dividend Safety Checks?Simply Wall St.Don’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoHere's How We Evaluate China Gas Holdings Limited's (HKG:384) DividendSimply Wall St.Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance